site stats

Platinum refractory

Webb12 apr. 2024 · KEY POINTS Among patients with platinum-refractory disease, objective response rates were 13.2% with the combination vs 18.3% with nivolumab alone. Among patients with platinum-eligible disease, objective response rates were 20.3% vs … WebbFör 1 dag sedan · The median OS in platinum-refractory patients was 10.0 months with ipilimumab plus nivolumab and 9.6 months with nivolumab alone (HR, 1.08; 95% CI, 0.80-1.46).

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single …

Webbplatinum refractory. Hi gals, I stumbled across this abstract on topo, and found it interesting. Ovarian cancer is the fifth leading cause of cancer death in women. Most … WebbThe outcome of patients with platinum refractory germ cell cancer who relapse after or are no candidates for stem-cell transplantation is dismal. No significant progress has been made within the last years. The use of anti-PD-1 antibodies has led to complete remissions and long-term disease control in patients with non-small-cell lung cancer, renal cell … nancy merritt bowie tx https://wjshawco.com

Recent developments in the treatment of small cell lung cancer

WebbFor the analysis of HNC patients treated with platinum-based regimens, platinum-refractory populations were defined as patients with records of other systemic therapy within 6 months from the last dosing date of the previous platinum agent in any setting, because information on disease progression, such as radiographs, is not available from … Webb3 jan. 2024 · Patients that progressed on therapy had less than a partial response or recurred within 6 months were considered platinum-resistant, while patients who had a previous partial or complete response and did not require chemotherapy for 6 months were considered potentially platinum-sensitive. WebbAfter 6 cycles of platinum-based chemotherapy, abdominopelvic CT revealed that the peritoneal carcinomatosis had progressed, and the patient began a regimen of 12 cycles of doxorubicin (40 mg/m 2 every 4 weeks) and 23 cycles of bevacizumab (10 mg/kg every 2 weeks) as 2nd-line chemotherapy. Second-line chemotherapy was also ineffective, and … nancy merse

Recurrent Ovarian Cancer Clinical Cancer Research American ...

Category:Activity of immune checkpoint inhibition in platinum refractory …

Tags:Platinum refractory

Platinum refractory

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade …

Webbplatinum-resistant or platinum-refractory ovarian cancer.1 The investigators faced a clinically relevant issue for medical and gynaecological oncologists; for decades, this … Webb1 juli 2024 · Abstract. Although high-grade serous ovarian cancers (HGSOC) are highly chemosensitive with an 85% initial response rate to platinum-based chemotherapy, 15% of patients are “exceptional nonresponders,” with platinum-refractory tumors that remain stable or progress during treatment. Unfortunately, we have no predictive biomarkers to …

Platinum refractory

Did you know?

Webb11 apr. 2024 · BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal treatment options for recurrent platinum-resistant ovarian cancer.MethodsPubmed, … WebbPts refractory to 1L therapy have a poor prognosis and are challenging to treat; we report relevant outcomes in such pts, including those with adenocarcinoma, from REVEL. Material (patients) and methods: Refractory pts had progressive disease as best response to platinum-based treatment.

WebbBackground: Previous locoregional treatment could affect the response to nivolumab in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The aim of this study is to evaluate the impact of the clinicopathological characteristics and previous treatment in predicting early progression to nivolumab in a … Webb30 maj 2024 · Univariable and multivariable analyses were performed to assess the effect of patient characteristics (time from diagnosis to platinum resistance, OC subtype, …

Webb29 nov. 2004 · In platinum-sensitive patients, defined as those patients relapsing ≥6 months after completing platinum therapy, overall tumor response rates ranged from 19% to 33% . Additionally, topotecan is active in platinum-refractory patients, yielding tumor response rates of 14% to 18% (15, 16, 56, 57). Webb1 apr. 2024 · All patients were platinum-refractory, with the exception of five patients who received apatinib as first-line (one patient had an active hepatitis B infection; one patient who was older than 70 years with moderate hypertension; one patient had G1 thrombocytopenia and G2 leukopenia; and two patients declined chemotherapy due to …

WebbAbstract. Platinum drug-based chemotherapy plays a dominant role in OC (ovarian cancer) treatment. The expression of DNA damage repair (DDR) genes is critical in distinguishing drug-sensitive and drug-refractory patients, as well as in the development of drug resistance in long-term treated patients.

Webb10 aug. 2012 · Ovarian cancer patients with platinum-resistant and -refractory disease have the lowest response rates to salvage chemotherapy. Various chemotherapeutic agents, such as paclitaxel, liposomal doxorubicin, topotecan, docetaxel, platinum, etoposide, ifosfamide, gemcitabine, and vinorelbine, are available and result in response … megatraveller starship operator\u0027s manual pdfWebbIn the population with platinum-refractory R/M SCCHN, rates of any grade and grade 3 or 4 serious TRAEs were 8.2% (13 of 158 patients) and 5.7% (9 of 158), respectively, with nivolumab plus ipilimumab vs 9.8% (8 of 82) and 3.7% … megatrax indoor motocrossWebbIn one trial, this regimen produced a response rate of 12% in platinum-refractory patients. Other agents such as tamoxifen demonstrate response rates of 10-15% in those with platinum-resistant ... megatraveller character sheetWebb28 jan. 2024 · Participant has platinum-resistant (progression within one to six months after completing platinum-based therapy) or platinum refractory disease (progression … nancy mersonWebbRefractory Primary Peritoneal Carcinoma Platinum-Resistant Primary Peritoneal Carcinoma Recurrent Platinum-Resistant Primary Peritoneal Carcinoma Recent clinical studies Etiology Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter … megatray instructionsWebb25 feb. 2024 · Avelumab has shown antitumor activity in patients with relapsed or refractory ovarian cancer who have progressed after platinum-based chemotherapy . Apoptotic pathways The effectiveness of chemotherapy strongly depends on the ability of ovarian cancer cells to undergo drug-induced apoptosis ( Fig. 5 ) ( 105 – 107 ). megatrax family trailerWebb8 juli 2024 · The mainstay of treatment of platinum-resistant and -refractory advanced EOC is nonplatinum chemotherapy, including weekly paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, and topotecan—with overall response rates (ORRs) up to 20%. mega travel pass sheffield